Alpha Tau Medical Ltd. (NASDAQ:DRTS) Sees Significant Growth in Short Interest

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 67,100 shares, a growth of 30.5% from the October 15th total of 51,400 shares. Based on an average trading volume of 22,200 shares, the days-to-cover ratio is presently 3.0 days. Currently, 0.1% of the shares of the stock are short sold.

Analysts Set New Price Targets

DRTS has been the subject of a number of research reports. Piper Sandler reiterated an "overweight" rating and set a $7.00 price target on shares of Alpha Tau Medical in a research report on Thursday, August 15th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Alpha Tau Medical in a report on Wednesday, October 23rd.

Alpha Tau Medical Trading Up 2.7 %

Shares of NASDAQ DRTS traded up $0.06 on Friday, hitting $2.26. The company's stock had a trading volume of 15,869 shares, compared to its average volume of 31,159. The stock has a 50 day moving average of $2.28 and a 200-day moving average of $2.30. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $3.40. The company has a quick ratio of 11.60, a current ratio of 11.66 and a debt-to-equity ratio of 0.07.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. Equities research analysts anticipate that Alpha Tau Medical will post -0.48 EPS for the current year.

Hedge Funds Weigh In On Alpha Tau Medical

Institutional investors have recently made changes to their positions in the stock. Aptus Capital Advisors LLC lifted its position in Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company's stock worth $56,000 after buying an additional 10,000 shares during the period. Caprock Group LLC purchased a new stake in Alpha Tau Medical during the 2nd quarter worth $59,000. Financial Guidance Group Inc. boosted its holdings in Alpha Tau Medical by 83.7% in the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company's stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Levin Capital Strategies L.P. boosted its stake in shares of Alpha Tau Medical by 2.6% during the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company's stock valued at $999,000 after buying an additional 8,641 shares during the last quarter. 2.65% of the stock is owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.